Results 51 to 60 of about 167,106 (231)
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
, 2022 The conserved neurotransmitter serotonin has been shown to be an important modulator of lifespan in specific nutritional contexts; however, it remained unclear how serotonin signaling influences lifespan under normal conditions.
Saige S. Porter (14200154) +4 more
core +1 more source
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function. [PDF]
PLoS ONE, 2014 There is considerable interest in defining new agents or targets for antithrombotic purposes. The 5-HT2A receptor is a G-protein coupled receptor (GPCR) expressed on many cell types, and a known therapeutic target for many disease states.
Olivia A Lin +4 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli +8 more
wiley +1 more source
Blockade of 5-HT2A receptors inhibits emotional hyperthermia in mice [PDF]
The Journal of Physiological Sciences, 2019 This study determined whether blockade of 5-hydroxytryptamine 2A (5-HT2A) receptors attenuated hyperthermia and tachycardia responses to psychological stress in mice. For this purpose, male mice (C57BL/6N) were pre-instrumented with a telemetric probe to measure core body temperature and heart rate prior to experimentation. Vehicle or 5-HT2A antagonist,
Vanshika Sinh, Youichirou Ootsuka
openaire +2 more sources
Journal of Gastroenterology and Hepatology, EarlyView.The first Australian guidance document on the assessment and management of idiopathic gastroparesis (IGP) reconceptualises IGP as a sensorimotor disorder. It proposes a novel multidisciplinary treatment algorithm and 20 high‐consensus recommendations, addressing common overlapping disorders, and providing clear guidance on associated disordered eating ...
Trina Kellar +11 more
wiley +1 more source
Journal of Pharmacological Sciences, 2007 The effect of the serotonin 5-HT2A/2C-receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) on ∆9-tetrahydrocannabinol (THC)-induced catalepsy-like immobilization was studied in mice.
Nobuaki Egashira +5 more
doaj +1 more source
, 2022 The conserved neurotransmitter serotonin has been shown to be an important modulator of lifespan in specific nutritional contexts; however, it remained unclear how serotonin signaling influences lifespan under normal conditions.
Saige S. Porter (14200154) +4 more
core +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2260-2271, July 2026.Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto +5 more
wiley +1 more source
Biomolecules & Biomedicine, 2017 Lerimazoline is a sympathomimetic drug that belongs to the imidazoline class of compounds, and is used as a nasal decongestant. Studies on lerimazoline are rare, and its pharmacological profile is not completely understood.
Eldina Rizvić +3 more
doaj +1 more source